Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754543 | 1.00 | ALDH1A1 (0.61) | ALDH1A1HSD17B10CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL30829728 | 0.81 | SMN1; SMN2 (0.62) | ALDH1A1HSD17B10CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL11718702 | 0.81 | LMNA (0.58) | ALDH1A1HSD17B10CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL30829749 | 0.81 | LMNA (0.58) | ALDH1A1HSD17B10CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL24425191 | 0.81 | SMN1; SMN2 (0.62) | ALDH1A1HSD17B10CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL23043060 | 0.81 | ALDH1A1 (0.58) | ALDH1A1HSD17B10CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL7936559 | 0.81 | PDPK1 (0.58) | ALDH1A1HSD17B10CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL6118333 | 0.80 | SMN1; SMN2 (0.59) | ALDH1A1HSD17B10CYP3A4TDP1SMN1; SMN2 | |
| SCHEMBL12109863 | 0.79 | NPC1 (0.49) | ALDH1A1HSD17B10TDP1SMN1; SMN2LMNA | |
| SCHEMBL25081101 | 0.78 | ALDH1A1 (0.54) | ALDH1A1HSD17B10CYP3A4TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759111-A1 | PHARMACEUTICAL COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-01-06 | — | — | EP | claimed |
| EP-1178977-B1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH AS (DK) | 2005-06-01 | — | — | EP | claimed |
| US-6759422-B2 | ADMINISTERING BENZOTHIAZOLE COMPOUND FOR THERAPY, PROPHYLAXIS OF DISEASE | NEUROSEARCH A/S (DK) | 2004-07-06 | — | — | US | claimed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| US-20030008906-A1 | Ion channel modulating agents | NEUROSEARCH A/S | 2003-01-09 | — | — | US | claimed |
| US-20020061914-A1 | Ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-05-23 | — | — | US | claimed |
| EP-1178977-A1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2002-02-13 | — | — | EP | claimed |
| WO-2000069838-A1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-11-23 | — | — | WO | claimed |
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INST NAT SANTE RECH MED (FR) | 2025-12-18 | — | — | US | disclosed |
| EP-4460500-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2024-11-13 | — | — | EP | disclosed |
| CN-118660885-A | Norbornene analogs and their use as potentiators of antitubercular drugs | 国家医疗保健研究所 | 2024-09-17 | — | — | CN | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
| EP-3294728-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| WO-2000069838-A1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| US-4086241-A | Benzothiazolylimidazolidinone esters of furyl and thienyl substituted acids | VELSICOL CHEMICAL CORPORATION (US) | 1978-04-25 | — | — | US | disclosed |
| US-4055569-A | HERBICIDE | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-25 | — | — | US | disclosed |
| US-4054574-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4045446-A | 1-Benzothiazolyl-5-pyridylcarbonyloxyimidazolidinones | VELSICOL CHEMICAL CORPORATION (US) | 1977-08-30 | — | — | US | disclosed |
| US-4029491-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | BBOX1, NDUFB6, NDUFB5 | ALDH1A1 108/4885HSD17B10 227/4885CYP3A4 343/4885 |
| US-20020061914-A1 | Ion channel modulating agents | KCNN1, KCNJ2, KCNN2 | ALDH1A1 4274/4885HSD17B10 3867/4885CYP3A4 3663/4885 |
| US-20030008906-A1 | Ion channel modulating agents | KCNN1, KCNJ2, KCNN2 | ALDH1A1 4208/4885HSD17B10 3762/4885CYP3A4 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.